Tags

Type your tag names separated by a space and hit enter

Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.
J Clin Pathol. 2009 Jul; 62(7):624-8.JC

Abstract

AIM

Basal-like breast tumours, as defined by microarrays, carry a poor prognosis and therapeutic options are limited to date. Often, these tumours are defined as oestrogen receptor (ER) negative/progesterone receptor (PR) negative/human epidermal growth factor receptor 2 (HER-2) negative (triple negative) by immunohistochemistry (IHC), but a more complete definition should include expression of basal cytokeratins (CK5/6, CK14 or CK17) and/or human epidermal growth factor receptor 1 (HER-1). The aim of this study was to investigate to what extent CK5/6 and HER-1 characterise the group of triple negative breast cancers.

METHODS

Expression of CK5/6 and HER-1 was studied by IHC in 25 triple negative breast carcinomas and 32 grade-matched, non-triple-negative controls. All 57 cases were further subjected to fluorescence in situ hybridisation to investigate HER-1 gene copy number.

RESULTS

CK5/6 and HER-1 expression was most frequent in triple negative tumours: 22 out of 25 cases (88.0%) expressed at least one of these markers (60.0% CK5/6 positive and 52.0% HER-1 positive). In the control group, CK5/6 and HER-1 expression was found in ER-negative but not in ER-positive tumours (ER negative/PR negative/HER-2 positive tumours: 20.0% CK5/6 positive and 46.7% HER-1 positive). HER-1 gene amplification was found in five cases only: four triple negative (16.0%) and one ER-negative control (ER negative/PR negative/HER-2 positive, 6.7%). Of interest, all five HER-1 amplified cases showed a remarkably homogeneous HER-1 expression pattern.

CONCLUSION

Expression of CK5/6 and HER-1 is frequent in ER-negative breast cancers, in triple negative and in non-triple negative tumours. In a minority of cases, HER-1 overexpression may be caused by HER-1 gene amplification. Further studies are needed to investigate whether such cases might benefit from anti-HER-1 therapy.

Authors+Show Affiliations

Department of Pathology, UZ Leuven, Leuven, Belgium.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19561231

Citation

Pintens, S, et al. "Triple Negative Breast Cancer: a Study From the Point of View of Basal CK5/6 and HER-1." Journal of Clinical Pathology, vol. 62, no. 7, 2009, pp. 624-8.
Pintens S, Neven P, Drijkoningen M, et al. Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1. J Clin Pathol. 2009;62(7):624-8.
Pintens, S., Neven, P., Drijkoningen, M., Van Belle, V., Moerman, P., Christiaens, M. R., Smeets, A., Wildiers, H., & Vanden Bempt, I. (2009). Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1. Journal of Clinical Pathology, 62(7), 624-8. https://doi.org/10.1136/jcp.2008.061358
Pintens S, et al. Triple Negative Breast Cancer: a Study From the Point of View of Basal CK5/6 and HER-1. J Clin Pathol. 2009;62(7):624-8. PubMed PMID: 19561231.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1. AU - Pintens,S, AU - Neven,P, AU - Drijkoningen,M, AU - Van Belle,V, AU - Moerman,P, AU - Christiaens,M-R, AU - Smeets,A, AU - Wildiers,H, AU - Vanden Bempt,I, PY - 2009/6/30/entrez PY - 2009/6/30/pubmed PY - 2009/10/8/medline SP - 624 EP - 8 JF - Journal of clinical pathology JO - J Clin Pathol VL - 62 IS - 7 N2 - AIM: Basal-like breast tumours, as defined by microarrays, carry a poor prognosis and therapeutic options are limited to date. Often, these tumours are defined as oestrogen receptor (ER) negative/progesterone receptor (PR) negative/human epidermal growth factor receptor 2 (HER-2) negative (triple negative) by immunohistochemistry (IHC), but a more complete definition should include expression of basal cytokeratins (CK5/6, CK14 or CK17) and/or human epidermal growth factor receptor 1 (HER-1). The aim of this study was to investigate to what extent CK5/6 and HER-1 characterise the group of triple negative breast cancers. METHODS: Expression of CK5/6 and HER-1 was studied by IHC in 25 triple negative breast carcinomas and 32 grade-matched, non-triple-negative controls. All 57 cases were further subjected to fluorescence in situ hybridisation to investigate HER-1 gene copy number. RESULTS: CK5/6 and HER-1 expression was most frequent in triple negative tumours: 22 out of 25 cases (88.0%) expressed at least one of these markers (60.0% CK5/6 positive and 52.0% HER-1 positive). In the control group, CK5/6 and HER-1 expression was found in ER-negative but not in ER-positive tumours (ER negative/PR negative/HER-2 positive tumours: 20.0% CK5/6 positive and 46.7% HER-1 positive). HER-1 gene amplification was found in five cases only: four triple negative (16.0%) and one ER-negative control (ER negative/PR negative/HER-2 positive, 6.7%). Of interest, all five HER-1 amplified cases showed a remarkably homogeneous HER-1 expression pattern. CONCLUSION: Expression of CK5/6 and HER-1 is frequent in ER-negative breast cancers, in triple negative and in non-triple negative tumours. In a minority of cases, HER-1 overexpression may be caused by HER-1 gene amplification. Further studies are needed to investigate whether such cases might benefit from anti-HER-1 therapy. SN - 1472-4146 UR - https://www.unboundmedicine.com/medline/citation/19561231/Triple_negative_breast_cancer:_a_study_from_the_point_of_view_of_basal_CK5/6_and_HER_1_ L2 - https://jcp.bmj.com/lookup/pmidlookup?view=long&pmid=19561231 DB - PRIME DP - Unbound Medicine ER -